Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22
Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $25 to $22.
Read original at benzingaStocks · News reference
Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14
Barclays analyst Glen Santangelo maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Overweight and lowers the price target from $18 to $14.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 17, 2026, 1:57 PM
- Checked
- Aug 17, 2026, 1:57 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.
Read original at benzingaNeedham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22
Read original at benzinga